Outcomes of patients with cancer undergoing left atrial appendage closure: a systematic review and meta-analysis

Clicks: 1
ID: 323371
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #214 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Patients with cancer and atrial fibrillation (AF) face a challenging trade-off between thromboembolic and bleeding that may limit long-term oral anticoagulation (OAC) maintenance. Left atrial appendage closure (LAAC) represents a potential valid alternative in this group; however, comparative outcomes remain sparse. Objectives To compare outcomes after LAAC in patients with cancer versus those without cancer. Methods We interrogated three electronic databases from inception through December 22, 2025, for studies reporting outcomes in AF patients undergoing LAAC according to cancer status. Outcomes were pooled using random-effects models with restricted maximum likelihood variance estimation. Prespecified time points were in-hospital, 30 days, and 1 year. The primary endpoint was in-hospital all-cause mortality. Results Nine observational studies (193,721 patients, 2,500 with cancer) were included. In-hospital mortality was higher in cancer patients (RR 2.12, 95% CI 1.26-3.56), remaining elevated also at 1-year (RR 1.69, 95% CI 1.15–2.49; I²=18.8%). In-hospital stroke and systemic embolism were also higher in cancer patients (RR 1.62, 95% CI 1.09-2.40; I²=0% and RR 2.01, 95% CI 1.09-3.70; I²=0%), with risk attenuation by 30 days. In-hospital bleeding did not differ significantly (RR 2.70, 95% CI 0.93-7.90); however, this occurred in the context of high heterogeneity (I²=92.4%). Conclusions Cancer patients with AF undergoing LAAC experience worse short- and mid-term outcomes compared to non-cancer patients. Prospective studies with standardized endpoint definitions and cancer-specific stratification are needed to define the net clinical benefit of this strategy in this subset of patients.
Reference Key
openalex_W7172312565 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M Camilli, G Occhipinti, E F Umanzor, C Laudani, L Amore, F Andreotti, T Lopez Fernandez, M Sitges, X Freixa
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.186
URL
https://doi.org/10.1093/eurheartjsupp/suag097.186
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.